Results 51 to 60 of about 1,454 (181)

Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice

British Journal of Pharmacology, EarlyView.
Background and Purpose Migraine is a neurovascular disorder largely mediated by calcitonin gene‐related peptide (CGRP). This study explores the role of the nociceptin/orphanin FQ (N/OFQ)–N/OFQ receptor (NOP) system in CGRP‐induced periorbital mechanical allodynia (PMA) in mice.
Chiara Sturaro, Pietro Pola, Michela Argentieri, Alessia Frezza, Matilde Marini, Francesco De Logu, Valentina Albanese, Marie Soukupova, Davide Malfacini, Nurulain T. Zaveri, Romina Nassini, Dane D. Jensen, Pierangelo Geppetti, Girolamo Calò, Chiara Ruzza   +14 more
wiley   +1 more source

Pharmacological Management of Acute Migraine: A Systematic Review Comparing NSAIDs, Triptans, Gepants, and Opioids

Journal of Education, Health and Sport
Background. Migraine is a complex neurobiological disorder associated with the activation of the trigeminovascular system. Many new publications about new drugs appear, but not all of them assign the drug to the most appropriate group of patients ...
Wiktor Kowalczyk, Weronika Olech, Julia Kępska, Aneta Synakiewicz, Natalia Lewińska, Aleksandra Pociej, Arina Drobashko, Nikola Murawska, Kamil Wójcik, Nicole Bulińska   +9 more
doaj   +1 more source

Real‐world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire‐5

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background The introduction of calcitonin gene‐related peptide antagonists has transformed migraine care. Zavegepant, a third‐generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real‐world data are limited.
Eric Dunn, Bradley Ong, Harpreet Kaur, Roman Popov, Claire Sonneborn, Aarushi Suneja   +5 more
wiley   +1 more source

Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Researchers are searching for blood tests that can show what is happening in migraine and help predict who will benefit from preventive treatment, and blood amylin (a signaling molecule known to trigger migraine) has been shown to be elevated in people with chronic migraine.
Rogelio Domínguez‐Moreno, Tyla I. Alexander, William K. Karlsson, Haidar M. Al‐Khazali, Michael L. Garelja, Rune H. Christensen, Messoud Ashina, Debbie L. Hay, Håkan Ashina   +8 more
wiley   +1 more source

Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies

, 2023
Background: For many years triptans have been the cornerstone of acute migraine treatment. Nevertheless, treatment with triptans may not always be initiated due to contraindications (seen in approximately one fifth of patients) or inadequate response ...
Souza, Marcio Nattan Portes, de Boer, Irene, Verhagen, Iris Elsa, Ashina, Messoud   +3 more
core   +1 more source

Distribution and target engagement of peripherally administered fremanezumab in the cerebrospinal fluid of healthy volunteers

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Our objective was to describe the distribution of fremanezumab to the cerebrospinal fluid (CSF) in healthy volunteers, and investigate its engagement and stabilization of its target, calcitonin gene‐related peptide (CGRP). Fremanezumab is a CGRP‐targeting monoclonal antibody approved for migraine prevention.
Jacki Rorabaugh, Edward Hellriegel, Juline Bryson, Ryan Tiver, Hang Zeng, Xiaofeng Lu, Steve Barash, Giulia Ghibellini, Olga Szilagyi, Ignacio Echenique, Andrew H. Ahn, Peter J. Goadsby, Laura Rabinovich‐Guilatt   +12 more
wiley   +1 more source

Headache disorders among Indigenous communities: A scoping review undertaken with knowledge keeper guidance

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective We performed a scoping review of literature on headache etiology, classification, prevalence, and treatment in Indigenous communities in Canada, the United States, Australia, and New Zealand. Background In the United States, analysis of national prevalence indicates that Indigenous Americans lead all other racial/ethnic groups in ...
Maia Kelly, Candice M. Todd, Ojistoh Kahnawahere Horn, Emily Simmonds, Diane Longboat, Cynthia White, Suvendrini Lena   +6 more
wiley   +1 more source

CGRP en migraña: de la fisiopatología a la terapéutica [PDF]

, 2022
Introduction: It has been observed in recent years that levels of such molecules as calcitonin gene-related peptide (CGRP) and, to a lesser extent, the pituitary adenylate cyclase-activating peptide are elevated during migraine attacks and in chronic ...
Latorre, G., Belvís, R., Santos Lasaosa, S., Cuadrado, M. l., Díaz Insa, S., Viguera, J., Santos Lasaosa, Sonia, Láinez, J.M., Leira, R., Porta-Etessam, Jesús, Porta Etessam, J., Pozo Rosich, Patricia, Irimia, P., Láinez, J. M., Guerrero Peral, A. l., Pascual, J., Huerta, M., Pozo Rosich, P., Sánchez del Río, M., Gago Veiga, Ana Beatriz, Gago Veiga, A., Pascual Gómez, Julio   +21 more
core   +1 more source

The MIND study: Design, feasibility, and baseline characteristics of a smartphone‐based migraine cohort

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Our objective was to describe the design, feasibility, and baseline characteristics of the Migraine Impact on Neurocognitive Dynamics study, a 30‐day smartphone‐based, prospective, decentralized, observational cohort study evaluating high‐frequency assessment of cognition and symptoms in adults with migraine.
Babak Khorsand, Devin Teichrow, Richard B. Lipton, Ali Ezzati   +3 more
wiley   +1 more source

Calcitonin gene-related peptide-targeting drugs for migraine:how pharmacology might inform treatment decisions

, 2022
Migraine is the second most disabling disorder across all age groups worldwide. Since 2018, two classes of drugs that inhibit the actions of calcitonin gene-related peptide (CGRP), which is implicated in migraine pathophysiology, have become available ...
Al-Hassany, Linda; id_orcid, MaassenVanDenBrink, Antoinette, Goadsby, Peter J., Maassen van den Brink, Antoinette, Goadsby, Peter J.; id_orcid, Danser, A.H. Jan, Danser, A. H.Jan, Al-Hassany, Linda, Peter J Goadsby, Antoinette MaassenVanDenBrink, Linda Al-Hassany, A H Jan Danser   +11 more
core   +1 more source